Onchocerciasis is a severe parasitic infection which causes disabling skin and subcutaneous tissue changes. The disease is endemic in many African countries including Ethiopia. In 2013, Ethiopia launched Onchocerciasis elimination program with the goal of attaining interruption of onchocerciasis transmission nationwide by 2020. The country has successfully scaled up interventions and achieved 100% geographic coverage in all known endemic districts. The main strategy for interrupting the disease is mass drug administration (MDA) delivered two times per year. The treatment coverage for the last five years has been maintained at more than 80%. Despite many years of ivermectin MDA the transmission of onchocerciasis in many districts remained unabated. To achieve the 2020 goal, sustained high geographic and therapeutic coverage is required which is validated by coverage surveys. The programme should aim to improve the knowledge and attitude of the community towards the programme in order to improve drug compliance. The partnership between the relevant stakeholders should be strengthened to facilitate open discussions regarding the programme implementation and any challenges that may arise in the control and elimination of the disease. It is also important to consider intensified vector control.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582636PMC

Publication Analysis

Top Keywords

onchocerciasis elimination
8
onchocerciasis
5
review ethiopian
4
ethiopian onchocerciasis
4
programme
4
elimination programme
4
programme onchocerciasis
4
onchocerciasis severe
4
severe parasitic
4
parasitic infection
4

Similar Publications

Article Synopsis
  • - The survey in Gabon between January and February 2020 studied infections from geohelminths in five communities where onchocerciasis is common, confirming endemicity through IgG testing and detecting soil-transmitted helminths (STHs) using Kato-Katz methods.
  • - Results showed a high prevalence of STHs at 64.8%, particularly in hypoendemic (80.9%) and hyperendemic (63.9%) areas. Hookworms were more common among males, and adults faced higher infection rates (75.9%) compared to the elderly (39.3%).
  • - The study suggests that a combined approach for eliminating STHs and onchocerciasis, through
View Article and Find Full Text PDF

Background: Entomological data for onchocerciasis surveillance relies on sampling black flies through human landing collectors in the field and laboratory testing of the flies for infection using pooled screening O-150 PCR-ELISA assay. Both techniques require improvements. This study aimed to optimize the Esperanza Window Trap (EWT) for black fly collection.

View Article and Find Full Text PDF
Article Synopsis
  • Onchocerciasis and lymphatic filariasis (LF) are diseases prevalent in Equatorial Guinea, with efforts historically focused on Bioko Island, which has successfully interrupted onchocerciasis transmission, prompting a need to assess mainland regions where transmission status is unclear.
  • The study, conducted from September to December 2019, employed various diagnostic methods on a sample of 3,951 individuals to estimate the prevalence of these diseases on the mainland, marking the first cross-sectional analysis for this area.
  • Results showed a very low onchocerciasis seroprevalence of 0.3%, and while no O. volvulus microfilariae were found in biopsies, DNA evidence confirmed its presence in one
View Article and Find Full Text PDF

is the agent of onchocerciasis (river blindness) and targeted by WHO for elimination though mass drug administration with ivermectin. A small percentage of adult worms develop pleomorphic neoplasms (PN) that are positively associated with the frequency of ivermectin treatment. Worms with PN have a lower life expectancy and a better understanding about the proteins expressed in PN, and how PN affect protein expression in different tissues could help to elucidate the mechanisms of macrofilaricidal activity of ivermectin.

View Article and Find Full Text PDF

Onchocerciasis (river blindness) is a debilitating tropical disease that causes significant eye and skin damage, afflicting millions worldwide. As global efforts shift from disease management to elimination, vaccines have become crucial supplementary tools. The Onchocerciasis Vaccine for Africa (TOVA) Initiative was established in 2015, to advance at least one vaccine candidate initially targeting onchocerciasis in infants and children below 5 years of age, through Phase I human trials by 2025.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!